When: Prior $100.26 breakout trigger now elevated to $99.92 due to ATR regime

Then: Re-engage with position build

Reduce position by 10-15% (not 25-40%) and implement automated risk parameters: full exit below $86.03, rebuild above $99.92, cap at 75% benchmark weight until credit metrics improve

• Recommends 10-15% trim rather than aggressive 25-40%, arguing larger reductions at bottom of basing pattern will whipsaw the position
• Hard floor: any close below $86.03 (200 SMA) on above-average volume forces immediate full exit — no discretion
• Re-engagement trigger: any confirmed daily close above $99.92 (50 SMA) with above-average volume reverses trim and rebuilds toward benchmark weight
• Position size cap: cannot exceed 75% of benchmark weight until Net Debt/FCF falls below 2.5x OR medical cost trend turns neutral
• Deleveraging at $730 million/month is a measurable, real credit improvement that argues for patience
• Stock in $92-$98 range with $2.38 ATR will touch $99.92 on reflexive bounce, triggering stops on larger trim positions
• PEG of 0.22 is built on implied earnings recovery from $3.79 to $8.52 — the gap is real but doesn't require full liquidation
• Conservative stance is about framework discipline, not magnitude of action

→ vs aggressive: 25-40% trim with stop at $99.92 will get tested in basing pattern — will crystallize losses on position trimmed from impatience rather than discipline; $99.92 stop is 9% away with elevated ATR making it almost certain to be touched on reflexive bounce, then reversed, leaving analyst as forced buyer of volatility

→ vs aggressive: Calling $730 million/month debt paydown 'years away from cleaning up balance sheet' misframes the goal — deleveraging is slow-moving protective moat, not moonshot; every quarter of paydown reduces tail risk and argues for patience

→ vs aggressive: Selling into weakness at bottom of basing pattern creates exactly the capitulation move aggressive analyst would want to buy back into — 'buying high and selling low with extra steps'

→ vs neutral: Waiting for 'clean trigger above $99.92 or below $91.68' is the most dangerous position — stocks making lower highs for six weeks with negative tangible book and $50 billion net debt do not give clean triggers; they chop sideways until suddenly they don't, and by time breakdown below $91.68 confirms, position has given back another 7-8%

→ vs neutral: Patience without posture is just unrecognized risk — sitting at 100% benchmark weight into deteriorating medical cost trend, stretched balance sheet, and 5% risk-free rate is not defensive, it's inertia dressed as wisdom

20% trim from current position weight

• 20% trim recommended as calibrated response between 10-15% conservative and 25-40% aggressive proposals
• 200 SMA at $86.03 established as hard floor with volume confirmation trigger (1.5x 20-day average required for full exit)
• 50 SMA at $99.92 designated as recovery trigger and dynamic trailing stop reference
• ATR compressed from $3.15 post-gap to $2.38, indicating volatility compression that historically precedes breakout or successful retest
• Time-based re-underwriting scheduled at Q3 earnings (late October/early November) with three specific evaluation questions
• Explicitly rejects Net Debt/FCF below 2.5x as re-engagement trigger, calling it 'asymptotic balance-sheet nirvana' that would prevent ever rebuilding position
• Seven sessions of positive MACD histogram while price holds above lower Bollinger Band acknowledged as valid momentum signal
• Position framing: medium-term trend broken but long-term structure intact, fundamentals recovering but operating environment hostile, technical picture damaged but not capitulated

→ vs aggressive: Dismissal of 200 SMA at $86.03 as just 'somewhere to fall to' is technically illiterate; the 200 SMA defines institutional trend-following behavior and high-leverage names approaching it typically see reflexive buying, not clean breaks

→ vs aggressive: Calling Q1/Q2 2026 operating income recovery and $5.65B Q2 2026 FCF 'hope' while cherry-picking depressed TTM EPS is contradictory; Q2 FCF annualizes to $22B+ against $122B market cap

→ vs conservative: Describing $730M/month debt paydown against $50B net debt as 'protective moat' understates the problem; at current pace it takes nearly six years to deleverage, with debt rolling at progressively higher rates in a 5%+ 10-year environment

→ vs conservative: 10-15% trim recommendation undertreats the actual risk of sitting at 85-90% benchmark weight in a name with deteriorating medical cost trends, stretched balance sheet, sector rotation bypassing it, and hostile rate environment

→ vs conservative: Re-engagement trigger of 'Net Debt/FCF below 2.5x OR medical cost trend neutral' is too restrictive; at current 3.1x ratio, reaching 2.5x takes years, making this an asymptotic trigger that effectively prevents position rebuilding